MedTrace Logo

Copeptin as a Biomarker for Central Diabetes Insipidus Development Following Pituitary Surgery

NCT04369703 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 199

Last updated 2022-06-03

No results posted yet for this study

Summary

1. Access the optimal cut point value of copeptin which predicts development of central diabetes insipidus postoperatively with highest accuracy.
2. Access the optimal cut point value of copeptin which predicts the lack of central diabetes insipidus postoperatively with highest accuracy
3. Access the relative change in copeptin values between baseline and post-surgery as a predictor for diabetes insipidus development.

Conditions

  • Sellar and Suprasellar Masses
  • Pituitary Tumor

Sponsors & Collaborators

Principal Investigators

  • Dana Erickson, M.D. · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-28
Primary Completion
2022-04-29
Completion
2022-04-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04369703 on ClinicalTrials.gov